Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results

Nuvation Bio (NYSE:NUVB) announced its quarterly earnings data on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04), FiscalAI reports. The business had revenue of $31.69 million during the quarter, compared to analyst estimates of $27.03 million. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
• Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
• Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
• The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
• Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Trading Down 4.4%

NUVB traded down $0.28 during mid-day trading on Thursday, reaching $6.09. The stock had a trading volume of 8,391,554 shares, compared to its average volume of 6,039,828. The firm’s fifty day simple moving average is $5.72 and its two-hundred day simple moving average is $5.23. The stock has a market capitalization of $2.12 billion, a P/E ratio of -14.16 and a beta of 1.52. Nuvation Bio has a 52 week low of $2.18 and a 52 week high of $9.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44.

Insider Transactions at Nuvation Bio

In other Nuvation Bio news, insider Stacy Markel sold 125,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.03, for a total transaction of $753,750.00. Following the completion of the sale, the insider directly owned 32,591 shares of the company’s stock, valued at approximately $196,523.73. The trade was a 79.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kerry Wentworth sold 63,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.02, for a total value of $379,260.00. Following the transaction, the insider owned 53,000 shares of the company’s stock, valued at $319,060. The trade was a 54.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 235,668 shares of company stock valued at $1,419,495 in the last three months. Company insiders own 30.11% of the company’s stock.

Institutional Investors Weigh In On Nuvation Bio

Institutional investors have recently added to or reduced their stakes in the stock. Rangeley Capital LLC bought a new stake in Nuvation Bio in the 2nd quarter valued at approximately $25,000. Parallel Advisors LLC increased its stake in Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after buying an additional 2,597 shares during the last quarter. Cetera Investment Advisers bought a new stake in Nuvation Bio during the 2nd quarter worth about $29,000. Captrust Financial Advisors bought a new stake in Nuvation Bio during the 2nd quarter worth about $32,000. Finally, Focus Partners Wealth acquired a new position in shares of Nuvation Bio during the 3rd quarter worth about $49,000. 61.67% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Truist Financial increased their target price on Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a research note on Thursday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nuvation Bio in a research note on Friday, July 17th. Zacks Research raised Nuvation Bio from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Nuvation Bio in a research note on Wednesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $12.88.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.